MENU
VTRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

VTRS stock forecast, quote, news & analysis

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
VTRS
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for VTRS with price predictions
Oct 09, 2026

VTRS in upward trend: 10-day moving average moved above 50-day moving average on September 22, 2026

The 10-day moving average for VTRS crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

VTRS moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +0.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where VTRS advanced for three days, in 223 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

The Aroon Indicator entered an Uptrend today. In 192 of 278 cases where VTRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.

Bearish Trend Analysis

The 10-day RSI Indicator for VTRS moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 22 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 55 cases where VTRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.

The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VTRS as a result. In 43 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.

The Moving Average Convergence Divergence Histogram (MACD) for VTRS turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 26 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

VTRS broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.471) is normal, around the industry mean (43.873). P/E Ratio (236.200) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (3.322) is also within normal values, averaging (2.152). VTRS has a moderately high Dividend Yield (0.026) as compared to the industry average of (0.005). P/S Ratio (1.347) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. VTRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

VTRS paid dividends on September 16, 2026

Viatris VTRS Stock Dividends
А dividend of $0.12 per share was paid with a record date of September 16, 2026, and an ex-dividend date of August 21, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.13B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 25%. APUS experienced the highest price growth at 56%, while SXTC experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 54%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 84%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 57
SMR Rating: 86
Profit Risk Rating: 83
Seasonality Score: 8 (-100 ... +100)
VTRS in upward trend: 10-day moving average moved above 50-day moving average on September 22, 2026